Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX(cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that investigators monitor BM or blood samples at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaojun Huang, Prof.
- Phone Number: 861088326006
- Email: lpxu_0415@sina.com
Study Contact Backup
- Name: Lanping Xu
- Phone Number: 861088326904
- Email: lpxu_0415@sina.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University Institute of Hematology,People's hospital Peking University
-
Contact:
- Lanping Xu, Prof.
- Phone Number: 8613641028627
- Email: lpxu_0415@sina.com
-
Contact:
- Yanru Ma
- Phone Number: 8613641134402
- Email: lpxu_0415@vip.sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
A:inclusion criteria
- Patients diagnosed as acquired severe aplastic anemia(SAA) /very vSAA
- patients with age 3-55 years
- patients have no matched sibling donor
- Patients have no matched unrelated donor
- patients have no severe infection
- Patients have no severe organ dysfunction
- patients have risk factors of potential intolerance to previous condition regimen including BuCy(200mg/kg)and ATG
- Consent form signed
B. Exclusion criteria :
- patients with congenital SAA/vSAA
- patients with age< 3years or >55 years
- patients with matched sibling donor
- patients with matched URD
- patients with severe infection
- patients with severe organ dysfunction
- pregnancy women
- no Consent form signed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BFCA regimen
Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d. BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT. |
Patients enrolled in this study would receive Bu (IV)0.8mg/kg
Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1 year cumulative incidence overall survival
Time Frame: 1 year post HSCT
|
Tne cumulative incidence of overall survival at 1 year post HSCT
|
1 year post HSCT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
one month Transplantation related mortality
Time Frame: 1 month post HSCT
|
Tne cumulative incidence of transplantation related motality at 1 month post HSCT
|
1 month post HSCT
|
|
Engraftment
Time Frame: 1 month post HSCT
|
Tne cumulative incidence of engraftment at 1 moths post HSCT
|
1 month post HSCT
|
|
0ne month regimen-related toxicity
Time Frame: 1 month post HSCT
|
Tne cumulative incidence of regimen related toxicity at 1 month post HSCT
|
1 month post HSCT
|
|
aGVHD
Time Frame: 100 days post HSCT
|
Tne cumulative incidence of acute GVHD at Day 100 post HSCT
|
100 days post HSCT
|
|
failure-free survival
Time Frame: 1 year post HSCT
|
The cumulative incidence of failure-free survival at 1year post HSCT
|
1 year post HSCT
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xiaojun Huang, Prof., Peking Universiy Institute of Hematology,People's Hospital Pekiking Universiyy
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Anemia
- Bone Marrow Failure Disorders
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
- Busulfan
- Thymoglobulin
Other Study ID Numbers
Other Study ID Numbers
- PUIH-SAA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.